T2DM

Journal of Otolaryngology Study Finds Surgical Treatment of Sleep Apnea More Effective than CPAP Therapy in Preventing the Onset of Type 2 Diabetes

Retrieved on: 
Thursday, June 1, 2023

The results were published in the article titled: " Risk of Diabetes in Patients with Sleep Apnea: Comparison of Surgery Versus CPAP in a Long-Term Follow-Up Study " in the Q1 medical Journal of Otolaryngology - Head and Neck Surgery.

Key Points: 
  • The results were published in the article titled: " Risk of Diabetes in Patients with Sleep Apnea: Comparison of Surgery Versus CPAP in a Long-Term Follow-Up Study " in the Q1 medical Journal of Otolaryngology - Head and Neck Surgery.
  • The study was led by Dr. Carlos O'Connor Reina, Laura Rodríguez Alcalá, Carlos Casado Morente, and José María Ignacio García.
  • Quirónsalud is the leading hospital group in Spain, and with its parent company Fresenius-Helios, also the leader in Europe.
  • "These findings will ultimately assist healthcare providers with making informed clinical decisions and personalized treatment plans for sleep apnea patients."

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

Retrieved on: 
Thursday, May 25, 2023

SAN FRANCISCO and SHANGHAI, China, May 25, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus (T2DM) who are overweight or obese. The Company has also initiated an ethnobridging study of GSBR-1290 in Japanese individuals and is planning to initiate an additional formulation bridging study to evaluate a tablet formulation of GSBR-1290 before the end of the year, both in preparation for the planned global Phase 2b study in 2024.

Key Points: 
  • The Company has also initiated an ethnobridging study of GSBR-1290 in Japanese individuals and is planning to initiate an additional formulation bridging study to evaluate a tablet formulation of GSBR-1290 before the end of the year, both in preparation for the planned global Phase 2b study in 2024.
  • “The initiation of the Phase 2a clinical trial marks a major milestone in our mission to bring an effective and convenient oral therapy to patients living with type 2 diabetes and obesity,” said Mark Bach, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics.
  • “We are excited to advance GSBR-1290, an orally available small molecule GLP1 agonist, into the next stage of clinical development.
  • This is the first program in our GLP-1 incretin franchise, and evaluating GSBR-1290 in Japanese patients demonstrates our commitment to rapidly developing this treatment globally.”

Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Thursday, May 11, 2023

SAN FRANCISCO and SHANGHAI, May 11, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • SAN FRANCISCO and SHANGHAI, May 11, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.
  • “We are rapidly advancing GSBR-1290, our lead program in our oral GLP-1 franchise,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics.
  • Topline data from the Phase 1b MAD and Phase 2a studies are expected in the second half of 2023.
  • R&D Expenses: Research and development expenses were $13.1 million for the first quarter ended March 31, 2023, as compared to $8.5 million for the same period in 2022.

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH

Retrieved on: 
Tuesday, May 2, 2023

BOSTON, May 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.

Key Points: 
  • The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis (NASH), in the third quarter of 2023.
  • "In Phase 1a/1b clinical studies, DA-1241 was well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM).
  • For these reasons, we believe that the mechanism of action of DA-1241 will translate into a safe and effective treatment for NASH.
  • We are eager to initiate the two-part, Phase 2a clinical trial of DA-1241, which we expect will occur in the third quarter of this year.

ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes

Retrieved on: 
Thursday, April 27, 2023

While lifestyle changes are often recommended to patients at this stage, there is a high degree of non-compliance.

Key Points: 
  • While lifestyle changes are often recommended to patients at this stage, there is a high degree of non-compliance.
  • Hypothesizing that a barrier to utilizing this therapy, for diabetic patients, would be the willingness to have a device implanted.
  • “The compelling data on our proprietary DBSN™ device, presented at the Keystone Symposia on Type 2 Diabetes, further validates the market potential of this technology,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • If approved for commercial use, the DBSN™ device will further enhance our differentiated medical device offerings.”

Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 30, 2023

SAN FRANCISCO and SHANGHAI, March 30, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate achievements.

Key Points: 
  • SAN FRANCISCO and SHANGHAI, March 30, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate achievements.
  • “Type 2 diabetes and obesity continue to grow rapidly worldwide and is a serious issue for all.
  • The Phase 1b study is designed to evaluate GSBR-1290 in multiple ascending doses to generate safety, pharmacokinetic and tolerability data.
  • Net Loss: Net loss totaled $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million, compared to $13.4 million for the fourth quarter of 2021 with non-cash stock-based compensation expense of $0.9 million.

Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28

Retrieved on: 
Tuesday, March 28, 2023

No patients on BMF-219 discontinued dosing and all patients completed 4 weeks of treatment.

Key Points: 
  • No patients on BMF-219 discontinued dosing and all patients completed 4 weeks of treatment.
  • Biomea plans to explore the potential clinical utility of BMF-219 in other diabetic patient populations, including type 1 diabetes.
  • Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

JMIR DIABETES | CLINICAL UTILITY OF DIGITAL THERAPEUTIC INTERVENTION WITH TYPE 2 DIABETES

Retrieved on: 
Wednesday, February 8, 2023

TORONTO and PHILADELPHIA, Feb. 8, 2023 /PRNewswire/ -- JMIR Publications published "Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study" in their journal JMIR Diabetes, which reported that patients with type 2 diabetes mellitus (T2DM) that have elevated levels of blood glucose and glycated hemoglobin are at higher risk of macro- and microvascular complications.

Key Points: 
  • TORONTO and PHILADELPHIA, Feb. 8, 2023 /PRNewswire/ -- JMIR Publications published "Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study" in their journal JMIR Diabetes , which reported that patients with type 2 diabetes mellitus (T2DM) that have elevated levels of blood glucose and glycated hemoglobin are at higher risk of macro- and microvascular complications.
  • The aim of this study was to examine the clinical utility of a digital therapeutic intervention (DTI) as an add-on therapy to achieve glycemic control in patients with T2DM.
  • This was a 12-week prospective, single-arm digital intervention study in patients with T2DM receiving regular antidiabetic treatment.
  • To learn more about JMIR Publications, please visit https://www.JMIRPublications.com or connect with us via:

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

Retrieved on: 
Wednesday, January 11, 2023

ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").

Key Points: 
  • ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH").
  • This double-blind, randomized, placebo-controlled, multicentre Phase 2b study will evaluate the effect of HTD1801, 1250 mg twice daily (BID), compared to placebo BID on histologic improvement in adult subjects with NASH and liver fibrosis who also have type 2 diabetes mellitus ("T2DM") or pre-diabetes.
  • The study will enroll approximately 210 subjects with biopsy-confirmed NASH and evidence of stage 2 or stage 3 liver fibrosis.
  • "Nonalcoholic fatty liver disease ("NAFLD") is the most prevalent chronic liver disease worldwide with a global prevalence of 25.2% to 29.8%.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

Retrieved on: 
Tuesday, January 10, 2023

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
  • Ph.D., MPH., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased to receive notice that this new patent will be granted.
  • As we already have patents covering similar indications in the U.S., Canada, Europe, Japan, China, and Korea, we believe this additional patent in Brazil could increase the potential value of MN-001.
  • A trial to evaluate the efficacy and safety of MN-001 in patients with T2DM, NAFLD, and HTG is currently ongoing.”